关注公众号
收藏产品 产品详情
优势与特点（FAB）
- Cost effective - Sufficient quantity at a lower price, accounting for dilution and pipetting losses.
- Comprehensive validation - Validated with various antibody subtypes and antibody drugs.
- Simple and fast operation - No complicated washing steps, significantly reducing time.
- High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
- Accurate and reliable results - High sensitivity with minimal matrix effects.
- High throughput capability - Supports 500 tests, ideal for high-throughput screening.
- Fast completion - Results in just 1 hour.
产品参数（Product Specifications）
Assay TypeInhibition-TR-FRETAnalyteHuman IgG, Human IgG Fc protein, Anti-human CD16a antibodyFormat100T/500TReactivityHumanRegulatory StatusRUOSensitivityIC50=390.4nMStandard Curve Range2.4414 nM-10000 nMAssay Time1 hrSuitable Sample TypeFor the binding of IgG Fc region to the human CD16aSample volume10 μL产品概述（Product Overview）
The Human Fc gamma RIIIA / CD16a (V176) binding Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to measure the interaction between human CD16a (V176) and antibody drug candidates or CD16a (V176) inhibitors. It is designed to facilitate the ADCC functional performance evaluation of antibody drug candidates, high-throughput screening of CD16a (V176) inhibitors within 0.5-1 hours. It can also be used as a universal detection tool to identify the ability of antibody drugs to bind to human CD16a (V176).
存储（Storage）
2-8℃
组分（Materials Provided）
IDComponentsSizeFRT07-C01Human Fc gamma RIIIA / CD16a (V176) Protein Europium-chelate100 tests/500 testsFRT07-C02FA labeled human IgG antibody100 tests/500 testsFRT07-C03Human IgG Standard400 μg/100 tests 2000 μg/500 testsFRT07-C04Sample Dilution Buffer10 mL/100tests & 500testsFRT07-C05Detection Buffer10 mL/100tests & 500testsIDComponentsSize原理（Assay Principles）
Human Fc gamma RIIIA / CD16a (V176) binding kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). Use the mixture of biotinylated human Fc gamma RIIIA / CD16a (V176) and Europium-chelate labeled streptavidin as the donor, FA labeled Human IgG1 antibody as the acceptor.
- In the absence of human Fc gamma RIIIA/CD16a (V176) binding components, the donor and acceptor are in close proximity due to the binding of human Fc gamma RIIIA/CD16a (V176) and FA-labeled Human IgG1 antibody. Upon excitation with a specific light source, the donor emits a 620 nm signal, which is absorbed by the acceptor, resulting in a 665 nm emission.
- In the presence of human Fc gamma RIIIA/CD16a (V176) binding components, they disrupt the donor-acceptor interaction, preventing FRET from occurring.
质量管理控制体系（QMS）
产品展示
活性（Bioactivity）-TR-FRET
Please refer to DS document for the assay protocol.
Inhibition Assay of interaction of Europium-chelate labeled human Fc gamma RIIIA / CD16a (V176) and FA labeled human lgG by Human IgG standard in a homogeneous (no wash) TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) competition assay, with a typical IC50 of 387.2 nM (QC tested).
The kit has been used to detect different subclasses of Human IgG (Human IgG1, Human IgG2, Human IgG3 and Human IgG4), which exhibit different IC50 results as expected. As shown in the figure, human CD16a (V176) binds to human IgG1, IgG2, IgG3 and IgG4 with low affinity, and IgG1 and IgG3 show the higher affinity than IgG2 and IgG4.
The kit has been used to detect different subclasses of mouse IgG, which exhibit different IC50 results as expected. The figure shows that human CD16a (V176) has very weak or no binding to mouse IgG1, mouse IgG2a, and mouse IgG2b as observed.
The kit has been used to detect four FDA approved antibody drugs with different affinities binding to human CD16a (V176). Bevacizumab and Efgartigimod alfa bind to human CD16a (V176) with the nanomolar affinity from 300nM to 700nM. Toripalimab doesn’t bind to human CD16a (V176). The Fc of Eculizumab has been modified into the human IgG2 hinge region and human IgG4 CH2-CH3 region, so it doesn’t bind to human CD16a (V176).
Verify potential matrix effects by adding different levels of DEME, RPMI1640, FBS and HSA to the Sample Diluted buffer.
用户评价 发表评论
背景介绍
CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibodydependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent
药物研发进展 
联系我们 
项目合作